Dialybrid Raises €15M Series A to Advance Silkothane Arteriovenous Graft for Hemodialysis

Dialybrid Closes €15M Series A

Dialybrid, a clinical-stage medical device company based in Cantù, Italy, has raised €15,000,000 in Series A funding. The round was led by XGEN Venture, with participation from CDP Venture Capital. The funding was announced on September 22, 2026.

What Dialybrid Does

Dialybrid develops novel arteriovenous vascular grafts for hemodialysis and other vascular applications. Its lead product, the Silkothane Arteriovenous Graft, is built on a patented hybrid material that combines resorbable silk fibroin with durable polyurethane. The goal is to give dialysis patients faster and longer-lasting vascular access.

Vascular access is a critical and recurring challenge for hemodialysis patients. Dialybrid's approach aims to improve outcomes by pairing a resorbable component with a durable polymer, a combination the company believes can extend the usable life of arteriovenous grafts.

Clinical Stage and Company Background

Dialybrid was founded in 2020 through a partnership between LIFTT, Bioengineering Laboratories, and founder Francesco Greco. The company began first-in-human clinical testing in 2026, marking a significant milestone for its lead Silkothane device.

Why This Round Matters

The Series A provides Dialybrid with capital to support its clinical-stage programs, including the ongoing first-in-human testing of the Silkothane Arteriovenous Graft. For a medical device company at this stage, funding is typically directed toward clinical trials, regulatory work, and manufacturing readiness.

The round also brings together a syndicate led by XGEN Venture with CDP Venture Capital, providing both venture backing and institutional support as Dialybrid moves through clinical development.

Investors

• Lead Investor: XGEN Venture
• Additional Investor: CDP Venture Capital

Company Snapshot

• Company: Dialybrid
• Domain: dialybrid.com
• Headquarters: Cantù, Italy
• Stage: Series A
• Round Type: Series A
• Amount Raised: €15,000,000 EUR
• Funding Date: September 22, 2026
• Lead Investor: XGEN Venture
• Founded: 2020
• Founding Partners: LIFTT, Bioengineering Laboratories, and founder Francesco Greco
• Lead Product: Silkothane Arteriovenous Graft

What to Watch

Dialybrid's progress will depend on the results of its first-in-human clinical testing, which began in 2026. The company's patented hybrid material—resorbable silk fibroin combined with durable polyurethane—is the core of its differentiation in the vascular graft market.

With €15 million in new capital, Dialybrid is positioned to advance clinical development and prepare for subsequent stages of regulatory and commercial planning. The involvement of XGEN Venture as lead and CDP Venture Capital as an additional investor gives the company a foundation to pursue its next milestones in hemodialysis and broader vascular applications.